XML 52 R25.htm IDEA: XBRL DOCUMENT v3.6.0.2
(LOSS) EARNINGS PER SHARE
 12 Months Ended
Dec. 31, 2016
Earnings Per Share [Abstract]  
(LOSS) EARNINGS PER SHARE
(LOSS) EARNINGS PER SHARE
(Loss) earnings per share attributable to Valeant Pharmaceuticals International, Inc. for the years ended December 31, 2016, 2015 and 2014 were calculated as follows:
(in millions, except per share amounts)
 
2016
 
2015
 
2014
Net (loss) income attributable to Valeant Pharmaceuticals International, Inc.
 
$
(2,409
)
 
$
(292
)
 
$
881

Basic weighted-average number of common shares outstanding
 
347.3

 
342.7

 
335.4

Dilutive effect of stock options and RSUs
 
—

 
—

 
6.1

Diluted weighted-average number of common shares outstanding
 
347.3

 
342.7

 
341.5

 
 
 
 
 
 
 
(Loss) earnings per share attributable to Valeant Pharmaceuticals International, Inc.
 
 
 
 
 
 
Basic
 
$
(6.94
)
 
$
(0.85
)
 
$
2.63

Diluted
 
$
(6.94
)
 
$
(0.85
)
 
$
2.58


In 2016 and 2015, all stock options, RSUs and convertible notes were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive. The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been as follows:
(in millions)
2016
 
2015
Basic weighted-average number of common shares outstanding
347.3

 
342.7

Dilutive effect of stock options and RSUs
2.8

 
6.1

Diluted weighted-average number of common shares outstanding
350.1

 
348.8


In 2016, 2015 and 2014, stock options, time-based RSUs and performance-based RSUs to purchase approximately 7,825,000, 1,587,000 and 1,192,000 common shares of the Company, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method.